YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Sitagliptin and Vildagliptin Use Evaluation among Dipeptidyl Peptidase 4 Inhibitors in Adult Koreans with Type 2 Diabetes Mellitus

한국인 제2형 당뇨병 환자에 대한 디펩티딜 펩티다제 4 억제제 중 Sitagliptin과 Vildagliptin의 약물 사용 평가

  • Park, Hyun-Jung (Clinical Pharmacy, College of Pharmacy, Chungbuk National University) ;
  • Lee, Ok-Sang (Clinical Pharmacy, College of Pharmacy, Chungbuk National University) ;
  • Lim, Sung-Cil (Clinical Pharmacy, College of Pharmacy, Chungbuk National University)
  • 박현정 (충북대학교 약학대학 임상약학실) ;
  • 이옥상 (충북대학교 약학대학 임상약학실) ;
  • 임성실 (충북대학교 약학대학 임상약학실)
  • Received : 2011.07.29
  • Accepted : 2012.04.23
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Type 2 Diabetes Mellitus (T2DM) is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. Diabetes is often initially managed by increasing exercise and dietary modification. As the condition progresses, medications may be needed such as oral sulfonylurea or others. Recently, dipeptidyl peptidase 4 (DPP- 4) Inhibitor is new drug which can control blood glucose by increasing the active levels of incretin hormone in the body. However, researches have been carried out for mostly Caucasian and Japanese, not for Koreans at all. Therefore, this study was to evaluate the efficacy and safety of DPP-4 inhibitor (Sitagliptin, Vildagliptin) in patients with T2DM in Koreans. This study was carried out retrospectively with reviewing of medical records from the 141 patients who received sitagliptin or vildagliptin over 24 week periods from January 2009, to December 2009. Information including demographics, concomitant medication, disease duration, and exercise was evaluated. $HbA_{1c}$, random blood glucose, post prandial 2 hour glucose, blood pressure, AST, ALT, serum creatinine, total cholesterol, triglyceride levels were also collected at baseline and endpoint (at 24 weeks). In each post-treatment group, $HbA_{1c}$, random blood glucose and post prandial 2 hour glucose levels were decreased significantly from baseline in the sitagliptin group (-0.82%, -28.76 mg/dl, -46.65 mg/dl) and vildagliptin group(-1.22%, -27.96 mg/dl, -67.2 mg/dl). Greater $HbA_{1c}$ mean reductions from baseline to 24 weeks were seen in patients with higher baseline values (>7.0%), with shorter disease durations (${\leq}1$ year) compared with those with lower baseline values (<7.0%), with longer disease durations (>1 year) in both sitagliptin and vildagliptin groups. The incidences of hypoglycemia, headache and upper respiratory infection were 0%, 8.7%, 5.8% in sitagliptin group and 2.8%, 8.3%, 6.9% in vildagliptin group. In conclusion, our results showed DPP-4 inhibitor provided similar efficacy compared with sulfonylurea after 24 weeks of treatment and were safer than sulfonylurea in hypoglycemia for Korean T2DM. Also vildagliptin was associated with significant improvement in $HbA_{1c}$ reduction in Korean patient with subgroup (body mass index<25 $kg/m^2$, metformin dose${\geq}$1000 mg, p<0.05) compared to sitagliptin. Therefore, even though DPP-4 inhibitor use for Korean needs to be studied more consistently in the future, DPP-4 inhibitor is a safe and effective drug for Korean T2DM based on our result.

Keywords

References

  1. King, H., Aubert, R. E. and Herman, W. H. : Global burden of diabetes (1998), 1995-2025. prevalence, numerical estimates, and projections. Diabetes Care 21, 1414 (1998).
  2. Rotella, D. P. : Approaches for the control of type 2 diabetes. Journal of Medicinal Chemistry 47, 4111 (2004).
  3. UK Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837 (1998).
  4. American Diabetes Association : Standards of medical care in diabetes 2008. Diabetes Car. 31 S12 (2008).
  5. Nathan, D. M., Buse, J. B. and Davidson, M. B. : Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consesus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29, 1963 (2006).
  6. Karasik, A., Aschner, P. and Katzeff, H. : Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Current Medical Research and Opinion 24, 489 (2008).
  7. Ahren, B. : Vildagliptin: novel pharmacological approach to treat type 2 diabetes. Therapy 5, 79 (2008).
  8. Deacon, C. F. and Holst, J. : Dipeptidyl peptidase-4 inhibitors: a promising new therapeutic approach for the management type 2 diabetes. International Journal of Biochemistry Cell Biology 38, 831 (2006).
  9. Deacon, C. F., Johnsen, A. H. and Holst, J. J. : Degradation of glucagon- like peptide-1 by human plasma in vitro yields an N terminally truncated peptide that is a major endogenous metabolite in vivo. Journal of Clinical Endocrinology & Metabolism 80, 952 (1995).
  10. National Institute for Health and Clinical Excellence NICE : Type 2 diabetes: newer agents (2009).
  11. Hanefeld, M., Herman, G. A. and Wu, M. : Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Current Medical Research and Opinion 23, 1329 (2007).
  12. Scott, R., Wu, L. and Sanchez, M. : Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice 61, 171 (2007).
  13. Aschner, P., Kipnes, M. S. and Lunceford, J. K. : Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29, 2632 (2006).
  14. Pratley, R. E., Jauffret-Kamel, S. and Galbreath, E. : Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Hormone and Metabolic Research 387, 423 (2006).
  15. Pi-Sunyer, F. X. and Schweizer, A. Mills : Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Research and Clinical Practice 76, 132 (2007).
  16. Dejager, S., Razac, S. and Foley, J. E. : Vildagliptin in drug-naive patients with type 2 diabetes; A 24 double-blind, randomized, placebo-controlled, multiple-dose study. Hormone and Metabolic Research 39, 218 (2007).
  17. Micromedex Healthcare Series: http;//www.micromedex.com.
  18. Charles, F. L., Lora, L. A. and Morton, P. G. : Drug information Handbook 15th edition, Lexi-comp; pp. 829-832, pp. 1010-1013 (2007).
  19. Mohan, V., Yang. W. and Son, H. Y. : Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Research Clinical Practice 83, 106 (2009).
  20. Richter, B., Bandeira-Echtler, E., Bergerhoff, K. and Lerch, C. L. : DPP-4 inhibitors for type 2 diabetes mellitus. Cochrane Database System Review, CD006789 (2008).
  21. Nakanishi, S., Okubo, M., Yoneda, M., Jitsuiki, K., Yamane, K. and Kohno, N. : Comparison between Japanese-American living in Hawaii and Los Angeles and native Japaneses: the impact of lifestyle westernization on diabetes mellitus. Biomedicine Pharmacotherapy 58, 571 (2004).
  22. Petersen, P. H., Jorgensen, L. G. and Brandslund, I. : De Fine Olivarius N, Stahl M, Consequences of bias and imprecision in measurements of glucose and HbA1c for the diagnosis and prognosis of diabetes mellitus. Scand J. Clin. Lab. Invest. Suppl. 240, 51 (2005).
  23. Sacks, D. B., Bruns, D. E., Goldstein, D. E., Maclaren, N. K., Mcdonald, J. M. and Parrott, M. : Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clinical Chemistry 48, 436 (2002).
  24. Sherifali, D., Nerenberg, K., Pullenayegum, E., Cheng, J. E. and Gestein, H. C. : The effect of oral antidiabetic agents on A1c levels. A systematic review and meta-analysis. Diabetes Care 33, 1859 (2010).
  25. Nauck, M. A., Meininger, G. and Sheng, D. : Efficacy and safety of DPP-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind study. Diabetes Obesity & Metabolism 9, 194 (2010).
  26. Monami, M., Iacomelli, I., Marchionni, N. and Mannucci, E. : Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A metaanalysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 20, 224 (2010).